Laci Michelle Turner

Ms. Laci Michelle Turner

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2023 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
CLChristine Loyd
Christine Loyd
KBKylie Blue
Kylie Blue
Laci Michelle TurnerLaci Michelle Turner
Laci Michelle Turner
AWAshley Weber
Ashley Weber
AGAshley Guy
Ashley Guy
CBCynthia Brown
Cynthia Brown

22 July 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Laci Michelle TurnerLaci Michelle Turner
Laci Michelle Turner
HTHanna Terhaar
Hanna Terhaar
VJVictoria Jiminez
Victoria Jiminez
BABailey J. Anderson
Bailey J. Anderson
Emily GrantEmily Grant
Emily Grant
NYNabiha Yusuf
Nabiha Yusuf
Background/Objectives: This review discusses the resistance mechanisms in the tumor microenvironment (TME) of malignant melanoma that disrupt the efficacy of immune checkpoint inhibitors (ICIs). In this review, we focus on the roles of immune cells, including tumor-infiltrating lymphocytes (TILs), macrophages, dendritic cells, and other signaling pathways. We explore the interplay between innate and adaptive immunity in the TME and tumor intrinsic resistance mechanisms, such as β-catenin, which has future implications for the usage of ICIs in patients with therapy-resistant tumors. Methods: A total of 1052 studies were extracted from the PubMed database searching for keywords and phrases that included [melanoma AND immune checkpoint inhibitor resistance]. After a title/abstract and full-text review, 101 studies were identified that fit the inclusion/exclusion criteria. Results: Cancer-associated fibroblasts (CAFs), M2 macrophages, and myeloid-derived suppressor cells (MDSCs) are significant in remodeling the TME to promote melanoma growth. Melanoma resistance to ICIs is complex and involves TME alterations, tumor intrinsic factors, and immune evasion. Key components of resistance include reduced CD8+ T cell infiltration, decreased host immune response, and immunosuppressive cytokines. Conclusions: Predictive biomarkers and specific models are the future of individualized melanoma management and show great promise in their approach to targeted therapy production. Tumor profiling can be utilized to help predict the efficacy of ICIs, and specific biomarkers predicting therapy responses are instrumental in moving towards personalized and more efficacious medicine. As more melanoma resistance emerges, alternative and combinatorial therapy based on knowledge of existing resistance mechanisms will be needed.

16 September 2025 in JMIR Dermatology
Verified
Journal Article
Open access
CMCharlotte McRae
Charlotte McRae
TZTing Dan Zhang
Ting Dan Zhang
LSLeslie Donoghue Seeley
Leslie Donoghue Seeley
MAMichael Anderson
Michael Anderson
Laci Michelle TurnerLaci Michelle Turner
Laci Michelle Turner
LGLauren V Graham
Lauren V Graham
Background: Artificial intelligence (AI) and telemedicine have significant potential to transform dermatology care delivery, but patient perspectives on these technologies have not been systematically compared. Objective: This study aimed to examine patient perspectives on AI and telemedicine in dermatology to inform implementation strategies as these technologies increasingly converge in clinical practice. Methods: A comprehensive literature search was conducted using PubMed, Scopus, and Embase databases between August 2024 and October 2024. We identified 48 papers addressing patient perspectives on AI and telemedicine in dermatology, with none directly comparing patients’ views of both technologies. Results: Several distinct themes emerged regarding patient perspectives on these technologies: willingness to use, perceived benefits and risks, barriers to implementation, and conditions necessary for successful integration. Findings revealed that patients express hesitancy toward AI-based diagnoses that lack dermatologist involvement, while preferences for teledermatology varied by reason for appointment, age, and previous technology exposure. Patients’ motivations for implementing AI are connected to its potential for quicker diagnoses and improved triage efficiency. At the same time, telemedicine addresses logistical challenges such as reduced travel time and improved appointment availability. Both technologies were perceived to improve accessibility and diagnostic efficiency, though patients expressed concerns about AI’s limited communication abilities and teledermatology’s inability to perform physical examinations. Primary adoption barriers for these modalities included technological limitations and trust concerns, with patients emphasizing the need for dermatologist oversight, transparency, and adequate educational resources for successful integration. Conclusions: The complementary strengths of AI and teledermatology suggest they could mitigate each other’s limitations when integrated—AI potentially enhancing teledermatology’s diagnostic accuracy, while teledermatology addresses AI’s lack of human connection. By thoroughly examining these perspectives, this review may serve as a guide for the patient-centered integration of technology in the future landscape of accessible dermatologic care.

6 January 2026 in Cells
Verified
Journal Article
Open access
PDF file
CSConnor Keaton Sisk
Connor Keaton Sisk
Laci Michelle TurnerLaci Michelle Turner
Laci Michelle Turner
SMShafkat Meraj
Shafkat Meraj
NYNabiha Yusuf
Nabiha Yusuf
Melanoma remains one of the deadliest cutaneous malignancies worldwide, and despite advances in systemic therapy, recurrence and treatment resistance remain frequent challenges. Following the success of COVID-19 mRNA vaccines, mRNA-based cancer vaccines targeting melanoma antigens have emerged as a promising therapeutic direction. This review summarizes current evidence on mRNA melanoma vaccines, focusing on two leading delivery platforms: lipid nanoparticles (LNPs) and dendritic cell (DC) vaccines. A comprehensive search of MEDLINE, Embase, and Scopus from 2015 to 2025 identified clinical trials, preclinical studies, and review articles evaluating mRNA vaccine constructs and delivery strategies. Completed clinical studies demonstrate that personalized LNP-formulated mRNA vaccines can enhance neoantigen-specific T-cell responses and improve recurrence-free survival, particularly when combined with immune checkpoint inhibitors. DC-based mRNA vaccines also show potent immunogenicity, with stronger responses observed when DC maturation is optimized. Ongoing trials continue to investigate next-generation LNP formulations, DC priming strategies, and personalized neoantigen approaches. Overall, current evidence indicates that both LNP and DC platforms can augment antitumor immunity by broadening T-cell responses and enhancing checkpoint inhibition. Continued refinement of delivery vehicles, neoantigen selection, and scalable manufacturing processes will be essential to realizing the full clinical potential of mRNA vaccines in melanoma.

8 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Laci Michelle TurnerLaci Michelle Turner
Laci Michelle Turner
CSConnor Keaton Sisk
Connor Keaton Sisk
NYNabiha Yusuf
Nabiha Yusuf
Background/Objectives: The gut microbiome influences melanoma biology and response to immune checkpoint inhibitors. Dietary fiber is a key modifiable factor that shapes the microbial composition and metabolite production. This review summarizes mechanistic, preclinical, and clinical evidence describing how fiber and fiber-responsive taxa may affect melanoma immunity and treatment outcomes. Methods: A literature search of MEDLINE, Embase, and Scopus identified studies published within the past five years examining dietary fiber, gut microbiome interactions, immune modulation, or melanoma outcomes. After screening 491 unique records, 49 peer-reviewed mechanistic, preclinical, observational, and interventional studies were synthesized qualitatively in this narrative review. Results: Fiber fermentation produces short-chain fatty acids that regulate dendritic cell activation, T-cell priming, and cytokine signaling. Preclinical melanoma models show that fibers such as inulin and β-glucan enhance IFN-γ-driven antitumor immunity, increase CD8+ infiltration, and improve checkpoint blockade efficacy in a microbiota-dependent manner. In humans, fiber-rich diets and enrichment of taxa such as Bifidobacterium, Faecalibacterium, and Akkermansia are associated with improved PD-1 inhibitor responses, longer progression-free survival, and possible reductions in ICI-related colitis. Although epidemiologic studies suggest no clear association between fiber intake and melanoma incidence, dietary fiber intake appears to correlate strongly with treatment-related outcomes. Conclusions: Dietary fiber represents a potentially safe and plausible adjunct to melanoma immunotherapy. However, study variability and emerging counterevidence highlight the need for controlled trials to clarify causality and define optimal fiber-based interventions.

1 March 2026 in Annals of Internal Medicine: Clinical Cases
Verified
Journal Article
Closed access
Laci Michelle TurnerLaci Michelle Turner
Laci Michelle Turner
CEClaire Estep
Claire Estep
GWGabby Westenberger
Gabby Westenberger
HRHinal Rathi
Hinal Rathi
NANessy Abraham-Philip
Nessy Abraham-Philip